Jenn Segar

15 posts

Jenn Segar

Jenn Segar

@JennSegar

Tucson, AZ 加入时间 Ağustos 2019
51 关注20 粉丝
Jenn Segar 已转推
Fabio Schutz
Fabio Schutz@FabioSchutz78·
Another presentation about the accuracy of PSMA PET for staging of localized prostate cancer. Sensitivity 40% / specificity 95%. PSMA PET should become SOC for high risk localized prostate cancer, and could significantly shift staging and change management. #ASCO20
Fabio Schutz tweet mediaFabio Schutz tweet mediaFabio Schutz tweet mediaFabio Schutz tweet media
English
5
65
144
0
Jenn Segar 已转推
NEJM
NEJM@NEJM·
Approximately 15 to 20% of gastric adenocarcinomas express HER2. In an RT, the antibody-drug conjugate led to higher response and longer overall survival than physician’s choice of therapy among patients with relapsed disease. #ASCO20
English
0
59
141
0
Jenn Segar 已转推
GTG
GTG@GrupoGTG·
Sobrero et al, final results of IDEA adjuvant collaboration: OS, DFS and toxicity results continue to support the use of 3m adjuvant CAPOX for the vast majority of stage III colon cancer pts. #ASCO20
GTG tweet mediaGTG tweet media
English
1
33
69
0
Jenn Segar 已转推
Aɴᴛᴏɴɪᴏ Pᴀssᴀʀᴏ
💥 #ASCO20 #LCSM ADAURA Clear improvement of DFS in favour OSI but many open questions are emerged. DFS was highly significant, of course potentially practice changing but... Would you feel safe to use Osi in adjuvant thinking about your patients/OS?
Aɴᴛᴏɴɪᴏ Pᴀssᴀʀᴏ tweet media
English
15
61
113
0
Jenn Segar 已转推
Fabio Schutz
Fabio Schutz@FabioSchutz78·
Updated results of Ph2 KeyNote-146 w/ Pembro-Lenvatinib in mRCC patients 2L/3L. Prior regimens: anti-PD1/L1 (100%), Anti-PD1/L1+anti-VEGFR (65%) and Ipi-Nivo (37%). Very high ORR 55%, including all cohorts #ASCO20. Should this combo be tested in 2L/3L in Ph3 trials?
Fabio Schutz tweet mediaFabio Schutz tweet mediaFabio Schutz tweet mediaFabio Schutz tweet media
English
3
39
81
0
Jenn Segar 已转推
Aɴᴛᴏɴɪᴏ Pᴀssᴀʀᴏ
🔥🔥 Kaboooom! #ASCO20 #LCSM Finally a target agent for HER2-mutated NSCLC: Interim results of DESTINY-Lung01 (42 pts) mDOR: 7.75 mo ORR: 61.9% DCR: 90.5% Estimated mPFS = 14.0 mo 👉All pts (42/42) had TEAEs; 64.3% were grade ≥ 3 (52.4% drug-related)
Aɴᴛᴏɴɪᴏ Pᴀssᴀʀᴏ tweet media
English
2
81
197
0
Jenn Segar 已转推
Duilio Rocha
Duilio Rocha@duiliorocha_onc·
#1 GI cancer practice-changing data in #ASCO20: total neoadjuvant therapy in rectal cancer. RAPIDO, PRODIGE, OPRA: TNT ⬆️pCR, ⬆️DFS, 3-y organ preservation in up to 59% pts. Questions: - Is triplet necessary? - Is short course RT reasonable as organ preservation strategy?
GTG@GrupoGTG

Bahadoer et al, phase 3 RAPIDO trial (abst 4006): Preoperative short-course radiotherapy followed by chemotherapy and TME resulted in lower rate of disease-related treatment-failure and distant metastasis and higher pCR rate over conventional CRT. #ASCO20

English
0
18
30
0
Jenn Segar 已转推
Stash
Stash@Stash·
#StashStockParty presents The Cantina After-Party ☠️⭐️🚀💥⚔️🧙‍♂️🎲🌑🍹🎺🎶🌌 --------------------------------------- • 4 parties tomorrow, every 30 min • Bring allies to boost the $$$ • Follow @Stash to stay briefed --------------------------------------- ⬇️⬇️⬇️#Maythe4th⬇️⬇️⬇️
Stash tweet media
English
81
406
663
0
Jenn Segar
Jenn Segar@JennSegar·
@AmericanAir Romantic trip to Maui starts with us being separated in middle seats despite us book our seats before through @CostcoTravel
English
0
0
0
0